Antimicrobial Susceptibility Testing Market Size | USD 6.24 Bn & 6.1% Growth

Global Antimicrobial Susceptibility Testing (AST)Market Size, Share, Trends, Growth Analysis | 2025-2035

Antimicrobial Susceptibility Testing (AST) is a vital diagnostic tool used in healthcare to determine the effectiveness of antibiotics and other antimicrobial agents against bacterial, fungal, and viral infections. With antimicrobial resistance (AMR) projected to claim millions of lives annually by 2050, the importance of AST has never been clearer. The role of AST in ensuring effective treatments, guiding antibiotic stewardship, and mitigating the spread of resistant infections is central to public health strategies worldwide. From 2025 to 2035, the Antimicrobial Susceptibility Testing market is expected to experience substantial growth, driven by technological advancements, increasing AMR prevalence, and the rising demand for personalized medicine. The global market, valued at $3.63 billion in 2024, is projected to expand at a 6.1% compound annual growth rate (CAGR), reaching $6.24 billion by 2034. This article delves into the dynamics of the AST market, analyzing key drivers, emerging trends, and future prospects, while highlighting the role of AST in combating the global AMR crisis.

Market Overview

The global Antimicrobial Susceptibility Testing (AST) market is undergoing significant transformation, primarily due to technological advancements in testing systems. Traditionally dominated by manual methods, AST is now shifting towards automated solutions, which are expected to represent a significant portion of the market share in the coming years. In 2023, automated systems accounted for 60% of market revenue due to their increased efficiency and accuracy. Clinical diagnostics is the leading application of AST, making up 45% of the market, largely driven by the growing prevalence of hospital-acquired infections and sepsis. North America holds the largest share of the market, contributing 38% of global revenue, thanks to advanced healthcare infrastructure and strong regulatory support. However, the Asia-Pacific region is emerging as the fastest-growing market, with a projected CAGR of 8.1%, fueled by increasing healthcare investments and rising AMR rates in countries like China and India. The demand for AST products and services is expanding across various segments, including instruments, reagents, clinical diagnostics, and drug development.

To learn more about this report - request a sample report PDF

Market Dynamics

Several factors are driving the expansion of the Antimicrobial Susceptibility Testing (AST) market. One of the primary drivers is the alarming rise in antimicrobial resistance (AMR), which is exacerbated by the overuse and misuse of antibiotics in both healthcare and agriculture. As AMR continues to pose a major public health threat, there is an urgent need for effective AST solutions to guide the appropriate use of antibiotics and curb resistance. AMR leads to prolonged hospital stays, increased healthcare costs, and higher mortality rates, making AST crucial in managing infections and optimizing treatment strategies. However, challenges such as the high cost of automated AST systems and the complexity of regulatory frameworks may limit market growth, particularly in low-income regions. Despite these challenges, opportunities exist in the form of rapid testing solutions that can significantly reduce the time required for susceptibility testing, enhancing the efficiency of treatment decision-making.

• Drivers: Rising antimicrobial resistance (AMR), accelerated by antibiotic misuse, necessitates Antimicrobial Susceptibility Testing (AST) adoption. The WHO’s Global Action Plan and $790 million in U.S. funding for antimicrobial resistance (AMR) research underscore governmental support. Demand for rapid diagnostics, like Accelerate Diagnostics’ Pheno® system (90-minute results), further propels growth.
• Restraints: High costs of automated systems ($50,000–$200,000) limit uptake in low-income regions. A shortage of skilled microbiologists in emerging markets exacerbates challenges.
• Opportunities: AI-powered platforms, such as bioMérieux’s Vitek REVEAL®, and point-of-care devices offer growth avenues. Emerging markets present untapped potential, with India’s Antimicrobial Susceptibility Testing (AST) demand growing 12% annually.
• Challenges: Regulatory complexities and a stagnant antibiotic pipeline (only 43 drugs in clinical trials in 2023) hinder progress.

Ecosystem Analysis

The Antimicrobial Susceptibility Testing (AST) ecosystem consists of a diverse group of stakeholders, including manufacturers, healthcare providers, regulatory bodies, and research organizations. Leading companies like bioMérieux, BD, and Thermo Fisher play a central role in driving innovation and improving testing technologies. Collaborations between public health organizations, such as the CDC’s Antibiotic Resistance Solutions Initiative, and private sector entities are crucial in advancing research and development in AST. Mergers and acquisitions, such as Danaher’s acquisition of Abcam, are helping to expand product portfolios and enhance diagnostic capabilities. Regulatory harmonization efforts, such as those led by the CLSI and EUCAST, are streamlining testing protocols and ensuring the reliability of AST solutions. As the market continues to evolve, partnerships and collaborations between stakeholders will be vital in addressing the growing threat of antimicrobial resistance.

Take Action Now: Secure your Global Antimicrobial Susceptibility Testing industry today – Purchase Now

Segmentation

The Antimicrobial Susceptibility Testing (AST) market can be segmented by product type, application, end-user, and region. In terms of product type, consumables, including culture plates, discs, cards, and reagents, are expected to hold the largest market share, accounting for nearly 50% of the market in 2025. Consumables are cost-effective, versatile, and essential for a wide range of microbial testing procedures, making them an indispensable part of AST workflows. Automated laboratory instruments are expected to grow at a 6.5% CAGR due to their precision and ability to process large sample volumes. The application segment is dominated by antibacterial susceptibility testing, driven by the high global burden of bacterial infections and the rising incidence of antibiotic-resistant strains. Hospitals remain the primary end-users of AST services, with a market share of 34%, followed by diagnostic laboratories and pharmaceutical companies. Geographically, North America holds the largest market share, followed by Europe, while the Asia-Pacific region is anticipated to experience the fastest growth due to increasing healthcare investments in countries like China and India.

• Product: Automated instruments (6.5% CAGR) lead; reagents hold 30% share due to recurring demand.
• Application: Clinical diagnostics dominate; drug development segments grow at 7.1% CAGR, spurred by pharma R&D.
• End-User: Hospitals (40% share) remain primary users; diagnostic labs expand with outsourcing trends.
• Region: Asia-Pacific’s growth is propelled by Japan’s AMR funding and China’s 1,200+ tertiary care hospitals.

Recent Developments (2023–2024)

In recent years, several significant developments have shaped the Antimicrobial Susceptibility Testing (AST) market. In 2023, BD launched automated AST solutions under the Kiestra™ brand, which reduced lab processing time by 50%, enhancing efficiency and throughput. The World Health Organization (WHO) introduced new AST protocols in 2024, specifically designed for low-resource settings, to support global efforts in combating AMR. The Accelerate Diagnostics Pheno® system received expanded FDA clearance in 2024, allowing for broader pathogen coverage and quicker results. Additionally, the EUCAST updated its 2023 breakpoints for 15 antibiotics, reflecting the evolving nature of antimicrobial resistance and the need for continuous updates in AST guidelines.

Recent Developments (2023–2024)

• BD Kiestra™: Automated solutions reduced lab processing time by 50%.
• WHO Guidelines: New AST protocols for low-resource settings launched in 2024.
• Accelerate Pheno®: FDA clearance for expanded pathogen coverage.
• EUCAST 2023 Breakpoints: Updated criteria for 15 antibiotics.

For Antimicrobial Susceptibility Testing Market Research Report and updates detailed: View Full Report Now!

Competitive Landscape

The Antimicrobial Susceptibility Testing (AST) market is highly competitive, with key players such as bioMérieux, BD, and Thermo Fisher dominating the market. These companies are focused on expanding their product portfolios, enhancing testing capabilities, and integrating advanced technologies like artificial intelligence and machine learning into their systems. Strategic initiatives, such as mergers and acquisitions, regional expansions, and research collaborations, are helping companies strengthen their market position. For example, BD allocated $1.2 billion to AST research and development in 2023, while Thermo Fisher has forged partnerships in India and Brazil to expand its presence in emerging markets. Additionally, emerging players like Accelerate Diagnostics are focusing on niche rapid-testing solutions to address the growing demand for faster and more accurate AST methods.

Top players (bioMérieux, BD, Thermo Fisher) control 55% of the market. Strategies include:

• R&D Investments: BD allocated $1.2 billion to AST in 2023.
• Regional Expansion: Thermo Fisher’s partnerships in India and Brazil.
• Product Launches: bioMérieux’s AMR Insights Platform (2024). Emerging players like Accelerate Diagnostics focus on niche rapid-testing solutions.

Conclusion and Future Outlook

The Antimicrobial Susceptibility Testing (AST) market is poised for significant growth over the next decade, driven by the increasing prevalence of antimicrobial resistance (AMR), technological advancements, and the rising demand for personalized medicine. While the adoption of automated and rapid testing solutions will play a key role in transforming the landscape of AST, affordability remains a major barrier in emerging economies. To overcome these challenges, stakeholders must focus on innovation, regulatory harmonization, and global collaborations. As AST continues to evolve, its impact on global health will be profound, with the potential to revolutionize infection management and combat the AMR crisis. The decade ahead will be critical in shaping the future of AST, with transformative changes expected in diagnostic technologies and healthcare delivery models.